- 1 Information about Rabeprazole
- 2 Liver safety of Rabeprazole
- 3 Mechanism of action of Rabeprazole
- 4 FDA approval information for Rabeprazole
- 5 Dosage and administration for Rabeprazole
- 6 Side effects of Rabeprazole
- 7 The antiulcer agents in clinical use
- 8 Articles on Rabeprazole
- 9 Learn more about Rabeprazole
Information about Rabeprazole
Rabeprazole is a proton pump inhibitor (PPI) and a potent inhibitor of gastric acidity used in the therapy of gastroesophageal reflux and peptic ulcer disease.
Liver safety of Rabeprazole
Rabeprazole therapy is associated with a low rate of transient and asymptomatic serum aminotransferase elevations and is a rare cause of clinically apparent liver injury.
Mechanism of action of Rabeprazole
Rabeprazole (ra bep' ra zole), like other PPIs, binds to and inactivates the H+/K+-ATPase of gastric parietal cells, causing inhibition of the proton pump that transports H+ into the gastric lumen, the final common step in gastric acid production. Rabeprazole is a prodrug and is converted to the active form in the acidic secretory canaliculi of parietal cells. Because the inhibition is irreversible, acid secretion is suppressed for 24 to 48 hours, until new proton pump molecules have been synthesized and transported to the cell membrane.
FDA approval information for Rabeprazole
Rabeprazole was the third PPI approved for use in the United States (1999) and is widely used in the therapy of acid-peptic disease, including duodenal and gastric ulcer disease and gastroesophageal reflux.
Dosage and administration for Rabeprazole
Rabeprazole is available in delayed release tablets of 20 mg in generic forms and under the brand name Aciphex. The typical dose for duodenal ulcer disease is 20 mg once daily for 4 to 8 weeks, with similar doses for long term maintenance therapy. Twice daily doses are used for more severe cases of gastrointestinal reflux and peptic ulcer disease, and doses of up to 120 mg daily for Zollinger-Ellison syndrome.
Side effects of Rabeprazole
Rabeprazole is very well tolerated. Side effects are uncommon and usually mild; they may include nausea, vomiting, abdominal discomfort, constipation, diarrhea, flatulence, skin rash, headaches and dizziness. Severe side effects are rare but can include hypersensitivity reactions. Long-term use of rabeprazole may be associated with bone fractures, acute interstitial nephritis, lupus erythematosus, vitamin B12 deficiency and hypomagnesemia
The antiulcer agents in clinical use